Although new antibiofilm agents have been developed to prevent and eliminate pathogenic
biofilms, their widespread clinical use is hindered by poor biocompatibility and …

Worldwide, the number of infections caused by biofilm-forming fungal pathogens is very
high. In human medicine, there is an increasing proportion of immunocompromised patients …

Candida auris is an emerging, multi drug resistant fungal pathogen that has caused
infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading …

Since Candida auris integrates strains resistant to multiple antifungals, research has been
conducted focused on knowing which molecular mechanisms are involved. This review aims …

Fungal infections impact the lives of at least 12 million people every year, killing over 1.5
million. Wide-spread use of fungicides and prophylactic antifungal therapy have driven …

Invasive fungal infections represent an expanding threat to public health. During the past
decade, a paradigm shift of candidiasis from Candida albicans to non-albicans Candida …

The number of effective therapeutic strategies against biofilms is limited; development of
novel therapies is urgently needed to treat a variety of biofilm-associated infections. Quorum …

Candida auris is a drug‐resistant pathogen with several reported outbreaks. The treatment
of C. auris infections is difficult due to a limited number of available antifungal drugs. Thus …

Candidiasis caused by Candida albicans infection has long been a serious human health
problem. The pathogenicity of C. albicans is mainly due to its virulence factors, which are …

Galleria mellonella is a model that uses adult larvae to assess the prophylactic, therapeutic,
and acute toxic potential of substances. Given their benefits, G. mellonella models are being …